Latest Breaking News On - Pa fibroscan - Page 1 : comparemela.com

Akero Therapeutics Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization and Lipoproteins

22% and 24% of patients experienced at least a one-stage improvement in liver fibrosis with no worsening of NASH by week 36, compared to 14% for placebo 4% of patients in each EFX dose group.

United statesSarah oconnellAndrew chengPa fibroscanStephen harrisonAustin murtaghAkero therapeutics incPinnacle clinical researchExchange commissionLiver biopsy analysis setNon invasive markersChange from baselineFull analysisSerum markersConference callSouth san

Akero Therapeutics (AKRO) Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study

Akero Therapeutics (AKRO) Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesAndrew chengPa fibroscanStephen harrisonAkero therapeutics incPinnacle clinical researchAkero therapeuticsLiver biopsy analysis setNon invasive markersChange from baselineFull analysisSerum markersConference call

Akero Therapeutics Phase 2b SYMMETRY Cohort D Study Met Safety & Tolerability Endpoints and Showed Adding EFX to GLP-1 Therapy Significantly Improved Non-Invasive Markers of NASH-Related Disease

Patients treated with EFX for 12 weeks combined with GLP-1 achieved a 65% relative reduction in liver fat, compared to a 10% relative reduction for GLP-1 alone 88% of patients treated with EFX. | June 5, 2023

United statesKitty yaleStephen harrisonPa fibroscanChristina tartagliaExchange commissionAkero therapeutics incPinnacle clinical researchFat fractionRelative changeRelative reductionLiver fatKey markersLiver injuryAbsolute changeKey cardio metabolic biomarkers

In Akero Therapeutics Phase 2b HARMONY Study, Both the 50mg and 28mg EFX Doses Achieved Statistical Significance on Primary and Secondary Histology Endpoints after 24 Weeks

50mg (41%) and 28mg (39%) groups demonstrated =1 stage improvement in fibrosis without worsening of NASH, double the placebo rate (20%) 50mg (76%) and 28mg (47%) groups demonstrated NASH resolution

United statesSarah oconnellAndrew chengLinkedinand twitterforStephen harrisonChristina tartagliaPa fibroscanExchange commissionAkero therapeutics incPinnacle clinical researchLiver fatKey markersChange from baselineFat fractionKey cardio metabolicConference call